




Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 15

Complete if Known

Application Number 10/560,332
Filing Date 09/08/2006
First Named Inventor Graeme Sample
Art Unit 1614
Examiner Name Unknown
Attorney Docket Number 59.US2.PCT

U.S. PATENT DOCUMENTS

| Examiner Initials ¹ | Cite No. ¹ | Document Number | Publication/Issue Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|--------------------------------|-----------------------|--|--------------------------------------|--|---|
| | | Number - Kind Code ² (if known) | | | |
| Y.C./ | AA | US-2005/0143443 A1 | 06-30-2005 | Fang et al., | |
| | AB | US-2004/0220186 A1 | 11-04-2004 | Bell et al., | |
| | AC | US-2002/0103215 A1 | 08-01-2002 | Gurram et al., | |
| | AD | US-6,200,980 B1 | 03-13-2001 | Piazza et al., | |
| | AE | US-5,846,990 | 12-08-1999 | Murugesan et al., | |
| | AF | US-5,464,860 | 11-07-1995 | Lepage et al., | |
| | AG | US-4,282,361 | 08-04-1981 | Hecht et al., | |
| | AH | US-4,238,506 | 12-09-1980 | Stach, deceased et al., | |
| | AI | US-3,980,646 | 09-14-1976 | Brenner et al., | |
| | AJ | US-3,637,714 | 01-25-1972 | Carlsson et al., | |
| | AK | US-2005/154024 | 07-14-2005 | Bryans et al., | |
| | AL | US-2005/182108 | 08-18-2005 | Carson et al., | |
| Y.C./ | AM | US-6,444,816 B1 | 09-03-2002 | Das et al., | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials ¹ | Cite No. ¹ | Foreign Patent Document | Publication Date/Filing Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | † |
|--------------------------------|-----------------------|---|---|--|--|---|
| | | Country Code ² - Number ³ - Kind Code ⁴ (if known) | | | | |
| Y.C./ | AN | WO 2004/085401 A1 | 10-07-2004 | Pfizer | | |
| | AO | WO 2004/078732 A1 | 09-16-2004 | Aventis Pharma S.A. | | |
| | AP | WO 2004/026829 A2 | 04-01-2004 | Boehringer Ingelheim Pharma GmbH & CO. KG | | |
| | AQ | WO 03/037899 A1 | 05-08-2004 | Pfizer | | |
| | AR | WO 03/037432 A1 | 05-08-2003 | Pfizer Products Inc. | | |
| | AS | WO 03/035065 A1 | 05-01-2003 | Aventis Pharma Inc. | | |
| | AT | WO 03/033484 A1 | 04-24-2003 | Bayer Aktiengesellschaft | | |
| | AU | WO 02/062799 A1 | 08-15-2002 | Dr. Reddy's Research Foundation | | |
| | AV | WO 99/54333 A1 | 10-28-1999 | Pfizer Limited | | |
| | AW | WO 98/49166 A1 | 11-05-1998 | Pfizer | | |
| Y.C./ | AX | WO 97/29748 A1 | 08-21-97 | Bristol-Myers Squibb Company | | |

| | | | |
|--------------------|------------|-----------------|------------|
| Examiner Signature | /Yong Chu/ | Date Considered | 02/20/2008 |
|--------------------|------------|-----------------|------------|

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ² Applicant's unique citation designation number (optional). ³ See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁷ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. Y.C./



PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2 of 15

Complete if Known

| | |
|------------------------|---------------|
| Application Number | 10/560,332 |
| Filing Date | 09/08/2006 |
| First Named Inventor | Graeme Semple |
| Art Unit | 1614 |
| Examiner Name | Unknown |
| Attorney Docket Number | 59.US2.PCT |

FEB 22 2007

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. | Foreign Patent Document | | Publication Date/Filing Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | † |
|--------------------|----------|---------------------------|---|---|--|---|---|
| | | Country Code ² | Number ³ - Kind Code ⁴ (if known) | | | | |
| /Y.C./ | AY | WO | 02/50091 A1 | 06-27-2002 | Glaxo Group Limited | | |
| | AZ | WO | 02/10171 A1 | 02-07-2002 | Pfizer | | |
| | BA | WO | 01/55136 A1 | 08-02-2001 | Syngenta Limited | | |
| | BB | WO | 01/49689 A2 | 07-12-2001 | Warner-Lambert Company | | |
| | BC | JP | 2004168706 A | 06-17-2004 | Nissan Chem Ind Ltd. | | |
| | BD | WO | 01/27113 A2 | 04-19-2001 | Pfizer | | |
| | BE | WO | 01/27101 A2 | 04-19-2001 | Pfizer | | |
| | BF | WO | 01/02369 A2 | 01-11-2001 | Agouron Pharma Inc. | | |
| | BG | JP | 2004217553 A | 08-05-2004 | Nissan Chem Ind LTD | | |
| | BH | JP | 57106665 A | 07-02-1982 | Showa Denko KK | | |
| | BI | JP | 02129171 A | 05-17-1990 | Nissan Chem Ind Ltd | | |
| | BJ | EP | 1475094 A1 | 11-10-2004 | Ustav Experimentálni Botaniky Akademie ved Ceske Republiky | | |
| | | | | | Ustav Experimentálni Botaniky Akademie ved Ceske Republiky | | |
| | BK | EP | 1348707 A1 | 10-01-2003 | Experimentalni Botaniky Akademie ved Ceske Republiky | | |
| | BL | EP | 1176142 A1 | 01-30-2002 | Pfizer | | |
| | BM | EP | 1092720 B1 | 01-12-2005 | Pfizer | | |
| | BN | EP | 0995750 A1 | 04-26-2000 | Pfizer | | |
| | BO | EP | 0994115 B1 | 03-02-2005 | Pfizer | | |
| | BP | EP | 0562833 A1 | 03-23-1993 | Sankyo Company Limited | | |
| | BQ | EP | 0463756 B1 | 06-07-1991 | Pfizer | | |
| | BR | EP | 0459887 A1 | 05-28-1991 | Novapharm | | |
| | BS | EP | 0442430 B1 | 02-11-1991 | Lonza AG | | |
| /Y.C./ | BT | EP | 0029364 A1 | 11-14-1980 | Morishita Pharma Co. LTD. | | |

| | | | |
|--------------------|------------|-----------------|------------|
| Examiner Signature | /Yong Chu/ | Date Considered | 02/20/2008 |
|--------------------|------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ² Applicant's unique citation designation number (optional). ³ See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard St. 3). ⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁷ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /Y.C./



Substitute for form 1449A (PTO 07-01)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 3

of 15

Complete if Known

Application Number 10/560,332
Filing Date 09/08/2006
First Named Inventor Graeme Semple
Art Unit 1614
Examiner Name Unknown
Attorney Docket Number 59.US2.PCT

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | | Publication Date/Filing Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ² |
|--------------------|-----------------------|---|--|---|---|---|----------------|
| | | Country Code ³ - Number ⁴ - Kind Code ⁵ (if known) | | | | | |
| /Y.C./ | BU | EP 0029363 A1 | | 11-14-1980 | Morishita Pharma Co. LTD. | | |
| | BV | DE 2604560 A1 | | 08-11-1977 | Boehringer Mannheim GmbH | | |
| | BW | DE 2559655 A1 | | 06-02-1977 | Fa. Johann A. Wullfing | | |
| | BX | DE 2512886 A1 | | 09-30-1976 | Fa. Johann A. Wullfing | | |
| | BY | WO 2003/032928 A1 | | 04-22-2004 | Arena Pharmaceuticals, Inc. | | |
| | BZ | GB 1048104 | | 11-09-1966 | The Upjohn Company | | |
| | CA | JP 54014968 | | 02-03-1979 | Taiho Pharmaceutical Co. Ltd. | | |
| | CB | WO2004/054974 | | 07-01-2004 | SmithKline Beecham Corporation | | |
| | CC | WO2005/009965 | | 02-03-2005 | Pfizer Ltd. | | |
| | CD | WO2005/084663 | | 09-15-2005 | Janssen Pharmaceutica | | |
| | CE | WO2006/023750 | | 03-02-2006 | Merck & Co., Inc. | | |
| | CF | WO2006/032519 | | 03-30-2006 | Hoffmann-La Roche | | |
| | CG | WO2006/032851 | | 03-30-2006 | Bioliopx AB | | |
| | CH | WO2006/032852 | | 03-30-2006 | Bioliopx AB | | |
| | CI | WO2006/052569 | | 05-18-2006 | Arena Pharmaceuticals, Inc. | | |
| | CJ | DE 2454137 A1 | | 05-20-1976 | Fa. Johann A. Wullfing | | |
| | CK | WO03/000659 | | 01-03-2003 | Nissan Chemical Industries | | |
| | CL | WO02/22601 | | 03-21-2002 | Vertex Pharmaceuticals, Inc. | | |
| | CM | WO00/69649 | | 11-23-2000 | Ortho-McNeil Pharmaceutical, Inc. | | |
| V | CN | WO03/099793 | | 12-04-2003 | Takeda Chemical Industries, Ltd. | | |
| | CO | WO2004/033431 | | 04-22-2004 | Arena Pharmaceuticals, Inc. | | |
| /Y.C./ | CP | HU1849408 | | 11-26-1984 | Gyogyszerkialato Intezet | | |

Examiner Signature

/Yong Chu/

Date

Considered

02/20/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. OO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /Y.C./



Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 4 of 15

Complete if Known

| | |
|------------------------|---------------|
| Application Number | 10/560,332 |
| Filing Date | 09/08/2006 |
| First Named Inventor | Graeme Sample |
| Art Unit | 1614 |
| Examiner Name | Unknown |
| Attorney Docket Number | 59.US2.PCT |



NON PATENT LITERATURE DOCUMENTS

| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|---------------------|-----------------------|---|----------------|
| /Y.C./ | CQ | HANING <i>et al.</i> , "Comparison of Different heterocyclic scaffolds as substrate analog PDE5 inhibitors," <i>Bioorganic & Medicinal Chemistry Letters</i> , (2005), 15(17), 3900-3907 | |
| | CR | WIERZCHOWSKI <i>et al.</i> , "Analogues of Formycins A and B: Synthesis and Some Properties of Methyl Derivatives of 7-Amino and 7-Keto Pyrazolo (4,3-d) Pyrimidines," <i>Acta Biochimica Polonica</i> , (1980), 27(1), 35-56 | |
| | CS | WIPF <i>et al.</i> , "Metathesis Reactions of Pyrazolotriazinones Generate Dynamic Combinatorial Libraries," <i>Organic Letters</i> , (2005), 7(20), 4483-4486 | |
| | CT | SIMENEL, "Erratum to 'Synthesis and enantiomeric resolution of ferrocenyl(alkyl)azoles," <i>Journal of Organometallic Chemistry</i> , (2004), 689(3), 702 | |
| | CU | WISE <i>et al.</i> , "Molecular Identification of High and Low Affinity Receptors for Nicotinic Acid," <i>Journal of Biological Chemistry</i> , (2003), 278(11), 9869-9874 | |
| | CV | SIMENEL <i>et al.</i> , "Synthesis and enantiomeric resolution of ferrocenyl(alkyl)azoles," <i>Journal of Organometallic Chemistry</i> , (2003), 688(1-2), 138-143 | |
| | CW | FRENCH <i>et al.</i> , "Effects of nutritional status and acute variation in substrate supply of cardiac and skeletal-muscle fructose 2,6-bisphosphate concentrations," <i>Biochemical journal</i> , (1988), 250(3), 773-9 | |
| | CX | HOLNESS <i>et al.</i> , "Regulation of renal and hepatic pyruvate dehydrogenase complex on carbohydrate re-feeding after starvation," <i>Biochemical journal</i> , (1987), 241(2), 421-5 | |
| | CY | HOLNESS <i>et al.</i> , "Effects of Administration of tri-iodothyronine on the response of cardiac and renal pyruvate dehydrogenase complex to starvation for 48 h," <i>Biochemical journal</i> , (1985), 232(1), 255-9 | |
| | CZ | SUGDEN <i>et al.</i> , "Effects of adrenaline on ketogenesis from long- and medium-chain fatty acids in starved rats," <i>The Biochemical journal</i> , (1982), 204(3), 749-56 | |
| /Y.C./ | DA | STEINFELDER <i>et al.</i> , "In Vitro Effects of Theophylline on Insulin Receptors in Adipocytes: Correlation with the Lipolytic action of the Agent," <i>Biochemical and biophysical research communications</i> , (1982), 104(1), 45-51 | |
| | DB | McALLISTER <i>et al.</i> , "The Effect of 5-Methylpyrazole-3-Carboxylate and Nicotinic Acid on Abnormalities of Carbohydrate Metabolism in Alloxan-Diabetic Rat Muscle," <i>Biochemical Pharmacology</i> , (1982), 31(1), 63-8 | |
| | DC | CREDNER <i>et al.</i> , "Salze der 5-Methylpyrazol-3-carbonsaure mit basisch substituierten Adenin-Derivaten," <i>Arzneimittel-Forschung</i> , (1981), 31(12), 2096-100 | |
| | DD | PODDAR <i>et al.</i> , "Potentiometric Investigation of Complex Equilibria Involving 5(3)- Methylpyrazole-3 (5)-carboxylic Acid with Some Metal Ions in Aqueous Solution," <i>Indian Journal of Chemistry, Section A: Inorganic, Physical, Theoretical & Analytical</i> , (1979), 18A(3), 252-4 | |

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /Y.C./



Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form PTO 449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 5 of 15

Complete if Known

Application Number 10/560,332
Filing Date 09/08/2006
First Named Inventor Graeme Sample
Art Unit 1614
Examiner Name Unknown
Attorney Docket Number 59.US2.PCT



NON PATENT LITERATURE DOCUMENTS

| Examiner Initials * | Cite No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|---------------------|----------|---|----------------|
| Y.C./ | DE | GRIMMETT <i>et al.</i> , "The N-Alkylation and N-Arylation of Unsymmetrical Pyrazoles," <i>Australian Journal of Chemistry</i> , (1979), 32(10), 2203-13 | |
| | DF | LEWIS <i>et al.</i> , "Synthesis of Pyrazolo (4,3-d) Pyrimidines via the Versatile Intermediate Ethyl 3-Methyl-4-nitropyrzazole-5-carboxylate," <i>Nucleic Acid Chem.</i> , (1978), 1, 121-8 | |
| | DG | ROSACK <i>et al.</i> , "Characterization of Lipolytic Responses of Isolated White Adipocytes from Hamsters," <i>Biochimica et Biophysica Acta, General Subjects</i> (1977), 496(2), 458-74 | |
| | DH | BIEROWSKA-CHARYTONOWICZ <i>et al.</i> , "Search for New Aminoguanidine Derivatives with Immunosuppressive and Cytostatic Properties," <i>Archivum Immunologiae et Therapiae Experimentalis</i> , (1976), 24(6), 871-81 | |
| | DI | GIUDICELLI <i>et al.</i> , "Effect of Pyrazole on ACTH Stimulated Lipolysis," <i>Biomedicine</i> , (Paris, France) (1973), 19(2), 48-51 | |
| | DJ | HITTELMAN <i>et al.</i> , "Effects of Antilipolytic Agents and a-Adrenergic Antagonists on Cyclic AMP Metabolism in Hamster White Adipocytes," <i>Biochimica et Biophysica Acta</i> , (1973), 316(3), 403-10 | |
| | DK | MENGEL <i>et al.</i> , "A Comparison of the Antilipolytic Effects of Nicotinic Acid, Methylisoxazole Carboxylic Acid, Methylpyrazole Carboxylic Acid and Insulin in Isolated Fat Cells," <i>Pharmacology</i> , (1972), 8(4-6), 280-90 | |
| | DL | GIUDICELLI <i>et al.</i> , "Effect of Pyrazole on Lipolysis," <i>Biochemical Pharmacology</i> , (1972), 21(15), 2095-102 | |
| | DM | LOTTI <i>et al.</i> , "Derivati Pirazolici Ad Attivita Ipoglicemizzante," <i>Farmaco, Edizione Scientifica</i> , (1972), 27(4), 313-16 | |
| | DN | CARLSON <i>et al.</i> , "Potential Hypolipidemic Agents," <i>Acta Pharmaceutica Suecica</i> , (1972), 9(4), 289-304 | |
| | DO | KRANZ <i>et al.</i> , "Pyrazolo (1,5-c)pyrimidin - ein neues heterocyclisches System," <i>Chemische Berichte</i> , (1972), 105(2), 388-405 | |
| | DP | BIZZI <i>et al.</i> , "Some Aspects of the Effect of Nicotine on Plasma FFA and Tissue Triglycerides," <i>Pharmacology</i> , (1972), 7(4), 216-24 | |
| | DQ | GARATTINI <i>et al.</i> , "Drugs Affecting Lipolysis," <i>Neuyn-Schmiedeberg's Archiv fuer Pharmakologie</i> , (1971), 269(2-4), 372-9 | |
| Y.C./ | DR | BIZZI <i>et al.</i> , "Drugs lowering plasma free fatty acids: Similarities and dissimilarities with nicotinic acid effect," <i>Metab. Eff. Nicotinic Acid Its Deriv.</i> , <i>Proc. Workshop</i> , (1971), Meeting Date 1970, 207-20 | |

| | |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. Y.C./



Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1449B/PITO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 6 of 15

Complete if Known

Application Number 10/560,332
Filing Date 09/08/2006
First Named Inventor Graeme Sample
Art Unit 1614
Examiner Name Unknown
Attorney Docket Number 59.US2.PCT

FEB 22 2007

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials * | Cite No. 1 | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T 2 |
|---------------------|------------|--|-----|
| Y.C./ | DS | FROESCH <i>et al.</i> , "Effects of nicotinic acid and structurally related drugs on adipose tissue in vitro and on carbohydrate and lipid metabolism of normal and diabetic rats in vivo," <i>Metab. Eff. Nicotinic Acid Its Deriv., Proc. Workshop</i> , (1971), Meeting Date 1970, 773-94 | |
| | DT | BUTCHER, "Effects of nicotinic acid on cyclic AMP levels in rat adipose tissue," <i>Metab. Eff. Nicotinic Acid Its Deriv., Proc. Workshop</i> , (1971), Meeting Date 1970, 347-55 | |
| | DU | GARATTINI <i>et al.</i> , "Nuove prospettive per il controllo farmacologico dei trigliceridi ematici," <i>Minerva Medica</i> , (1971), 62(72), 3431-2 | |
| | DV | MALAISSSE <i>et al.</i> , "Biochemical, Pharmacological, and Physiological Aspects of the Adenylcyclase-Phosphodiesterase System in the Pancreatic β -Cells," <i>Struct. Metab. Pancreatic Islets, Proc. Int. Symp.</i> , (1970), Meeting Date 1969, 435-44 | |
| | DW | TAMASI <i>et al.</i> , "Changes in serum triglyceride and cholesterol levels independently of free fatty acid after lipolysis inhibitors," <i>Biochemical Pharmacology</i> , (1970), 19(5), 1826-30 | |
| | DX | CARMENA <i>et al.</i> , "Effect of 5-methylpyrazole-3-carboxylic acid on plasma free fatty acids and blood sugar in geese," <i>Biochemical Pharmacology</i> , (1970), 19(5), 1838-40 | |
| | DY | LUYCKX <i>et al.</i> , "Facteurs influençant la sécrétion de glucagon pancréatique et extrapancréatique," <i>Acta Isotopica</i> , (1970), 10(3-4), 269-84 | |
| | DZ | KUPIECKI <i>et al.</i> , "Stimulation of lipolysis in adipose tissue in vitro by inhibitors of lipid mobilization," <i>Journal of Lipid Research</i> , (1970), 11(1), 38-41 | |
| | EA | HAVEL <i>et al.</i> , "Effects of 5-methylpyrazole-3-carboxylic acid (MPCA) on fat mobilization, ketogenesis and glucose metabolism during exercise in man," <i>Advan. Exp. Med. Biol.</i> , (1969), 4 105-15 | |
| | EB | TAMASI <i>et al.</i> , "Szabadzsírsav-csökkentő vegyületek hatása alloxan-diabéteses patkányokon," <i>Kísérletes Orvostudomány</i> , (1969), 21(3), 259-63 | |
| | EC | EASTWOOD <i>et al.</i> , "Some effects of 3-chloroisoxazole-5-carboxylic acid on lipid and carbohydrate metabolism," <i>Biochemical Pharmacology</i> , (1969), 18(3), 569-77 | |
| | ED | BIZZI <i>et al.</i> , "The hypersensitivity of adipose tissue to norepinephrine and other lipolytic agents during blockade of free fatty acids (FFA) mobilization," <i>Biochemical Pharmacology</i> , (1969), 18(9), 2053-60 | |
| | EE | TAMASI <i>et al.</i> , "Comparison of the Antilipemic Effect of Nicotinic Acid (NA) and 3-Methylpyrazole-5-Carboxylic Acid (MPCA) in rats," <i>Biochemical Pharmacology</i> , (1968), 17(9), 1789-94 | |
| Y.C./ | EF | BIZZI <i>et al.</i> , "Different responses of white and brown adipose tissue to drugs affecting lipolysis," <i>Biochemical Pharmacology</i> , (1968), 17(12), 2407-12 | |

| | |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. Y.C./

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 7 of 15

Complete if Known

Application Number 10/560,332
Filing Date 09/08/2006
First Named Inventor Graeme Sample
Art Unit 1614
Examiner Name Unknown
Attorney Docket Number 59.US2.PCT

FEB 22 2007

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|---------------------|-----------------------|---|----------------|
| /Y.C./ | EG | KUPIECKI <i>et al.</i> , "Effects of 5-Methylpyrazole-3-carboxylic acid (U-19425) and nicotinic acid on lipolysis in vitro and in vivo and on cyclic-3', 5'-AMP phosphodiesterase," <i>Journal of Pharmacology and Experimental Therapeutics</i> , (1968), 160(1), 166-70 | |
| | EH | SICKINGER, "Glucose requirement for prolonged blocking of lipolysis with 3,5-dimethylisoxazole and 5-methylpyrazole-3-carboxylic acid," <i>Klinische Wochenschrift</i> , (1968), 46(10), 563-5 | |
| | EI | BIZZI <i>et al.</i> , "Inhibition of fatty acid release by pyrazole derivatives," <i>Progress in Biochemical Pharmacology</i> , (1968), 4 573-7 | |
| | EJ | FANG, "Salicylate hypoglycemic action in alloxan-diabetic rats and structural relationships," <i>Archives Internationales de Pharmacodynamie et de Therapie</i> , (1968), 176(1), 193-208 | |
| | EK | TAMASI <i>et al.</i> , "3-(5)-Methyl-5-(3)-pirazol-karbonsav (MPK) patkanyok alloxan-diabeteses lipaemiajara gyakorlati hatasa," <i>Acta Pharmaceutica Hungarica</i> , (1968), 38(2-3), 166-70 | |
| | EL | BIZZI <i>et al.</i> , "3-Methyl-5-Carboxamidepyrazole, a long lasting inhibitor of lipolysis," <i>Farmacologia, Edizione Scientifica</i> , (1967), 22(9), 709-16 | |
| | EM | SMITH <i>et al.</i> , "Absorption, Metabolism, and Excretion of 5-Methylpyrazole-3-carboxylic Acid in the Rat, Dog, and Human," <i>Journal of Pharmaceutical Sciences</i> , (1967), 56(9), 1150-7 | |
| | EN | GERRITSEN <i>et al.</i> , "Development of Tachyphylaxis to the Antilipolytic, Hypoglycemic Agent, 5-Methylpyrazole-3-carboxylic Acid, U-19425," <i>Proceedings of the Society for Experimental Biology and Medicine</i> , (1967), 126(2), 524-9 | |
| | EO | HOLLOBAUGH <i>et al.</i> , "The Effect of a Pyrazole Derivative on Plasma Free Fatty Acids in Man," <i>Metabolism: Clinical and Experimental</i> , (1967), 16(11), 996-1000 | |
| | EP | TAMASI <i>et al.</i> , "Effects of 3-Carboxyl-5-Methylpyrazole (CMP) on Serum and Liver Lipids in Rats," <i>Medicina et Pharmacologia Experimentalis</i> , (1967), 16(6), 573-8 | |
| | EQ | HO <i>et al.</i> , "Insulin-Like Action of Quabain I. Effect on Carbohydrate Metabolism," <i>Biochimica et Biophysica Acta</i> , (1967), 144(1), 61-73 | |
| | ER | SPRIO <i>et al.</i> , "Transformazioni nucleari per idrogenolisi. Trasformazione del nucleo isossiazolico in nucleo piridazinico," <i>Annali di Chimica</i> , (Rome, Italy) (1967), 57(7), 846-54 | |
| | ES | BIZZI <i>et al.</i> , "Lowering of plasma triglycerides as a result of a decreased free fatty acid mobilization," <i>Journal of Pharmacy and Pharmacology</i> , (1966), 18(9), 611-14 | |
| /Y.C./ | ET | HABRAKEN <i>et al.</i> , "Pyrazoles II. Ionisation constants of pyrazolecarboxylic and pyrazoleacetic acids," <i>Recueil des Travaux Chimiques des Pays-Bas</i> , (1966), 85(11), 1194-6 | |

| | |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /Y.C./

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 8 of 15

Complete if Known

Application Number 10/560,332
Filing Date 09/08/2006
First Named Inventor Graeme Sample
Art Unit 1614
Examiner Name Unknown
Attorney Docket Number 59.US2.PCT

FEB 22 2007

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|---------------------|-----------------------|---|----------------|
| /Y.C./ | EU | VETULANI, "The metabolic activity of some isoxazole and pyrazole derivatives," <i>Dissertationes Pharmaceuticae et Pharmacologicae</i> , (1966), 18(6), 573-84 | |
| | EV | SMITH <i>et al.</i> , "5-Methylpyrazole-3-carboxylic Acid. The Potent Hypoglycemic Metabolite of 3,5-Dimethylpyrazole in the Rat," <i>Journal of Medicinal Chemistry</i> , (1965), 8(3), 350-3 | |
| | EW | TABAK <i>et al.</i> , "Chromatography of Pyrazole Derivatives on Acetylated Paper," <i>Journal of Chromatography</i> , (1965), 17(3), 520-7 | |
| | EX | FROESCH <i>et al.</i> , "Insulin Inhibition of Spontaneous Adipose Tissue Lipolysis and Effects upon Fructose and Glucose Metabolism," <i>Molecular Pharmacology</i> , (1965), 1(3), 280-96 | |
| | EY | SMITH <i>et al.</i> , "Metabolism of 3,5-dimethylpyrazole-C ¹⁴ in the rat," <i>Journal of Pharmacology and Experimental Therapeutics</i> , (1965), 150(2), 316-21 | |
| | EZ | HAMLIN <i>et al.</i> , "Relationship between in vitro dissolution rates and solubilities of numerous compounds representative of various chemical species," <i>Journal of Pharmaceutical Sciences</i> , (1965), 54(11), 1651-3 | |
| | FA | GERRITSEN <i>et al.</i> , "The effect of 5-Methylpyrazole-3-Carboxylic Acid on Carbohydrate and Free Fatty Acid Metabolism," <i>Journal of Pharmacology and Experimental Therapeutics</i> , (1965), 150(3), 491-8 | |
| | FB | MARSHUPTA <i>et al.</i> , "The solubility of propylene in aromatic hydrocarbons," <i>Khim. Prom.</i> , (1965), 41(8), 585-7 | |
| | FC | RINGEL <i>et al.</i> , "Darstellung und Aminolyse des 1,1,1-Trichloracetylacetons," <i>Journal fuer Praktische Chemie</i> , (Leipzig) (1964), 26(5-6), 333-9 | |
| | FD | GRANDBERG, "Pyrazoles XXXIV. Ultraviolet Spectra of Pyrazole Systems," <i>Zhurnal Obshchei Khimii</i> , (1963), 33 519-25 | |
| | FE | TABAK <i>et al.</i> , "Investigation of Pyrazoles XXV. Paper Chromatography of Pyrazolecarboxylic Acids," <i>Zhurnal Obshchei Khimii</i> , (1962), 32 1562-4 | |
| | FF | HOPFF <i>et al.</i> , "Über Decarboxylierung und Dissoziation heterocyclischer Dicarbonsauren," <i>Helvetica Chimica Acta</i> , (1961), 44 1058-63 | |
| ↓ | FG | D'AGOSTINO <i>et al.</i> , "Reducing activity in vitro of certain antibiotic and chemotherapeutic drugs," <i>Aggiorn. Pediat.</i> , (1961), 12(10), 477-84 | |
| /Y.C./ | FH | TERENTEV <i>et al.</i> , "Pyrazoles IX. New Method of Synthesizing Pyrazolecarboxylic Acids," <i>Zhurnal Obshchei Khimii</i> , (1960), 30 2925-31 | |

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete. Including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /Y.C./

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 9 of 15

Complete if Known

Application Number 10/560,332
Filing Date 09/08/2006
First Named Inventor Graeme Semple
Art Unit 1614
Examiner Name Unknown
Attorney Docket Number 59.US2.PCT



NON PATENT LITERATURE DOCUMENTS

| Examiner Initials * | Cite No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|---------------------|----------|---|----------------|
| /Y.C./ | FI | DAL MONTE <i>et al.</i> , "Ricerche sugli eterodidici: spettri di assorbimento U.V. e proprietà cromoforiche," <i>Gazzetta Chimica Italiana</i> , (1956), 86 797-848 | |
| | FJ | DAL MONTE <i>et al.</i> , "Ricerche nella serie dei pirazoli: Spettri U.V. di alcuni metal-, carbossi- e fenil-pirazoli," <i>Boletino Scientifico della Facolta di Chimica Industriale di Bologna</i> , (1954), 12 147-9 | |
| | FK | AINSWORTH <i>et al.</i> , "Reactions of Hydrazines with γ -pyrones," <i>Journal of the American Chemical Society</i> , (1954), 76, 3172-4 | |
| | FL | LLOYD <i>et al.</i> , "The Dissociation Constants of Cupric Salts of Some Monocarboxylic Acids," <i>Journal of the Chemical Society</i> , (1951), 1786-9 | |
| | FM | PINO, "Le Costanti di dissociazione di alcuni derivati della serie del pirazolo e dell' isossazolo," <i>Annali di Chimica</i> , (Rome, Italy) (1950), 40 575-92 | |
| | FN | HENRY <i>et al.</i> , "Aromatic Isocyanates as Reagents for the Identification of Some Heterocyclic Compounds," <i>Journal of the American Chemical Society</i> , (1949), 71, 2297-2300 | |
| | FO | HUTTEL <i>et al.</i> , "Über die Löslichkeit der Pyrazol- und Triazolaldehyde in Alkalien," <i>Ann.</i> , (1947), 558, 34-47 | |
| | FP | MUSANTE <i>et al.</i> , "La degradazione di Curtius applicata ad alcuni acidi pirazolicarbonici," <i>Gazzetta Chimica Italiana</i> , (1947), 77, 182-98 | |
| | FQ | MUSANTE, "Su alcuni acidi pirazolicarbonici e loro derivati," <i>Gazzetta Chimica Italiana</i> , (1945), 75, 121-36 | |
| | FR | DEWAR <i>et al.</i> , "Sulphanilamides of Some Aminopyrazoles, and a Note on the Application of <i>p</i> -Phthalimidobenzene-sulphonyl Chloride to the Synthesis of Sulphanilamides," <i>Journal of the Chemical Society</i> , (1945), 114-16 | |
| | FS | LANGLEY <i>et al.</i> , "Solubility of the Flavonates of Certain Organic Bases in Water, Ethanol, and <i>n</i> -Butanol at 3 and 30°," <i>Journal of the American Chemical Society</i> , (1942), 64, 2507-8 | |
| | FT | CUSMANO, "Transformation of acidi γ -isossiazolicarbonici in derivati del pirazolo," <i>Gazzetta Chimica Italiana</i> , (1940), 70, 235-40 | |
| ✓ | FU | AUWERS <i>et al.</i> , "Über Acyl-pyrazole," <i>Journal fuer Praktische Chemie</i> , (Leipzig) (1930), 126 146-76 | |
| /Y.C./ | FV | SAGI <i>et al.</i> , "Studies on the Metabolism of Azolecarboxylic Acids Closely Related to the Fusaric Acid (5-Butylpyridine-2-carboxylic Acid)," <i>Yakugaku Zasshi</i> , (1988), 108(4), 350-4 | |

| | |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /Y.C./

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 10 of 15

Complete if Known

Application Number 10/560,332
Filing Date 09/08/2006
First Named Inventor Graeme Sample
Art Unit 1614
Examiner Name Unknown
Attorney Docket Number 59.US2. PCT

FEB 22 2007

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|---------------------|-----------------------|---|----------------|
| Y.C./ | FW | YAMANAKA <i>et al.</i> , "Syntheses of Heteroaromatic Carboxylic Acids Closely Related to Fusaric Acid," <i>Chemical & Pharmaceutical Bulletin</i> , (1983), 31(12), 4549-53 | |
| | FX | KESKIN, "Semikarbazid'in α,γ -diketoasitler ve bunların etil esterleri üzerine etkimesi," <i>Rev. faculte Sci. Univ. Istanbul</i> , (1944), 9A, 81-9 | |
| | FY | HUO <i>et al.</i> , "Methyl 4-bromo-1,3-dimethylpyrazole-5-carboxylate," <i>Acta Crystallographica, Section E: Structure Reports Online</i> , (2003), E59(12), o2013-o2014 | |
| | FZ | EHLERT <i>et al.</i> , "Polynuclear pyrazolate complexes of copper. Crystal and molecular structures of...." <i>Canadian Journal of Chemistry</i> , (1992), 70(8), 2161-73 | |
| | GA | ROJAHN <i>et al.</i> , "Beitrag zur Kenntnis der Rosenmundschen Aldehydsynthese im heterocyclischen system," <i>Arch. Pharm.</i> , (1926), 264, 337-47 | |
| | GB | MORGAN <i>et al.</i> , "CLII.- Substitution in the Pyrazole Series. Halogen Derivatives of 3 : 5-Dimethylpyrazole," <i>Journal of the Chemical Society, Transactions</i> , (1923), 123 1308-18 | |
| | GC | BANKS <i>et al.</i> , "Fluorocarbon Derivatives of Nitrogen. Part 8. Reactions Between Heteroaromatic N-Imines (N-Iminopyridinium and N-Iminoquinolinium Ylide) and Perfluoropropene, 2H-Pentafluoropropene, Perfluorobut-2-ene, Perfluorobut-2-ene, Perfluorobut-2-yne, and Perfluoropyridine: Synthesis of Fluorinated 3-Azaindolizines (Pyrazolo[1,5-a]-pyridines)," <i>Journal of the Chemical Society, Perkin Transactions 1</i> , (1982), (7), 1593-600 | |
| | GD | FROESCH <i>et al.</i> , Effects of 5-methylpyrazole-3-carboxylic acid on adipose tissue. I. Inhibition of lipolysis, effects on glucose, fructose, and glycogen metabolism in vitro and comparison with insulin. <i>Molecular Pharmacol.</i> (1967), 3(5), 429-41 | |
| | GE | MUGNAINI <i>et al.</i> , Heterocyclic syntheses with propargyl alcohol and butynediol. II. <i>Classe sci. fis., mat. e nat.</i> (1953), 14, 275-80 | |
| | GF | MUGNAINI <i>et al.</i> , Heterocyclic syntheses with propargyl alcohol and butynediol. <i>Classe sci. fis., mat. e nat.</i> (1953), 14, 95-8 | |
| | GG | HUTTEL Über einige Aldehyde der Pyrazol- und der 1,2,3-Triazol-Reihe. <i>Berichte der deutschen chemischen Gesellschaft (A and B Series)</i> 74(10), 1941, 1680-1687 | |
| Y.C./ | GH | PANIZZI <i>et al.</i> , Heterocyclic syntheses. VII. Some pyrazolic ketones. <i>Gazzetta Chimica Italiana</i> (1946), 76, 66-77 | |

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 11 of 15

Complete if Known

| | |
|------------------------|---------------|
| Application Number | 10/560,332 |
| Filing Date | 09/08/2006 |
| First Named Inventor | Graeme Semple |
| Art Unit | 1614 |
| Examiner Name | Unknown |
| Attorney Docket Number | 59. US2.PCT |



NON PATENT LITERATURE DOCUMENTS

| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|---------------------|-----------------------|---|----------------|
| /Y.C./ | GI | MELANI <i>et al.</i> , Synthesis of 5H-10,11-dihydropyrazolo[5,1-c][1,4]benzodiazepine derivatives. II. <i>Journal of Heterocyclic Chemistry</i> (1984), 21(3), 813-15 | |
| | GJ | KLAGES <i>et al.</i> , Pyrazoles from 1:3-diketones and alkyl diazoacetates. <i>Journal fuer Praktische Chemie</i> (1902), 65(ii), 387-93 | |
| | GK | OWEN <i>et al.</i> , Olefinic acids. II. Reactivity of α -bromoacrylic acid and some related compounds. <i>Journal of the Chemical Society</i> (1947), 1030-4 | |
| | GL | ABDALLAH <i>et al.</i> , Diazoacetaldehyde dimethyl acetal: a new route to cyclopropane aldehydes and formylpyrazoles. <i>Tetrahedron Letters</i> (1980), 21(23), 2239-42 | |
| | GM | International Search Report, WO 2005/011677, 12/10/2004 | |
| | GN | ALTSCHUL <i>et al.</i> , Influence of nicotinic acid on serum cholesterol in man. <i>Archives of biochemistry</i> (1955), 54(2), 558-9 | |
| | GO | TAVINTHARAN <i>et al.</i> , The benefits of niacin in atherosclerosis. <i>Current atherosclerosis reports</i> (2001), 3(1), 74-82 | |
| | GP | CARLSON <i>et al.</i> , Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. <i>Journal of Internal Medicine</i> (2005), 258(2), 94-114 | |
| | GQ | LORENZEN <i>et al.</i> , Characterization of a G protein-coupled receptor for nicotinic acid. <i>Molecular Pharmacology</i> (2001), 59(2), 349-357 | |
| | GR | SOGA <i>et al.</i> , Molecular identification of nicotinic acid receptor. <i>Biochemical and Biophysical Research Communications</i> (2003), 303(1), 364-369 | |
| | GS | TUNARU <i>et al.</i> , PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. <i>Nature Medicine</i> (New York, NY, United States) (2003), 9(3), 352-355 | |
| | GT | ZHANG <i>et al.</i> , Niacin mediates lipolysis in adipose tissue through its G-protein coupled receptor HM74A. <i>Biochemical and Biophysical Research Communications</i> (2005), 334(2), 729-732 | |
| V | GU | BENYO <i>et al.</i> , GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing. <i>Journal of Clinical Investigation</i> (2005), 115(12), 3634-3640 | |
| /Y.C./ | GV | O'KANE <i>et al.</i> , A comparison of acipimox and nicotinic acid in type 2b hyperlipidaemia. <i>British journal of clinical pharmacology</i> (1992), 33(4), 451-3 | |

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.96. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /Y.C./

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 12

of

15

Complete if Known

| | |
|------------------------|---------------|
| Application Number | 10/560,332 |
| Filing Date | 09/08/2006 |
| First Named Inventor | Graeme Sample |
| Art Unit | 1614 |
| Examiner Name | Unknown |
| Attorney Docket Number | 59. US2.PCT |

FEB 22 2007

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|---------------------|-----------------------|---|----------------|
| Y.C.J. | GW | JIRKOVSKY <i>et al.</i> , Hypolipidemic 4,5-dihydro-4-oxo-5,5-disubstituted-2-furancarboxylic acids. <i>Journal of Medicinal Chemistry</i> (1982), 25(10), 1154-6 | |
| | GX | HUNNINGHAKE <i>et al.</i> , Controlled trial of acifran in type II hyperlipoproteinemia. <i>Clinical pharmacology and therapeutics</i> (1985), 38(3), 313-7 | |
| | GY | SEKI <i>et al.</i> , Studies on hypolipidemic agents. II. Synthesis and pharmacological properties of alkylpyrazole derivatives. <i>Chemical & Pharmaceutical Bulletin</i> (1984), 32(4), 1568-77 | |
| | GZ | VAN HERK <i>et al.</i> , Pyrazole Derivatives as Partial Agonists for the Nicotinic Acid Receptor. <i>Journal of Medicinal Chemistry</i> (2003), 46(18), 3945-3951 | |
| | HA | MAHBOUBI <i>et al.</i> , Triglyceride modulation by acifran analogs: activity towards the niacin high and low affinity G protein-coupled receptors HM74A and HM74. <i>Biochemical and Biophysical Research Communications</i> (2006), 340(2), 482-490 | |
| | HB | FROESCH <i>et al.</i> , Effects of 5-methylpyrazole-3-carboxylic acid on adipose tissue. II. Antilipolytic and hypoglycemic effects in vivo. <i>Molecular Pharmacol.</i> (1967), 3(5), 442-52 | |
| | HC | Beilstein Records (BRN): 10958, Chemical Name (CN): 4-methyl-5-propionyl-1(2)-H-pyrazole-3-carboxylic acid | |
| | HD | Beilstein Records (BRN): 14055, Chemical Name (CN): 4-methyl-5-propionyl-1(2)-H-pyrazole-3-carboxylic acid ethyl ester | |
| | HE | GERRITSEN <i>et al.</i> , Effects of 5-methylpyrazole-3-carboxylic acid, U-19425, on FFA [free fatty acid] mobilization. <i>Advan. Exp. Med. Biol.</i> (1969), 4 93-103 | |
| | HF | BIZZI <i>et al.</i> , Correlation between the effect of drugs on plasma free fatty acids and on tissue triglycerides. <i>Advan. Exp. Med. Biol.</i> (1969), 4 201-11 | |
| | HG | GUNDERSEN <i>et al.</i> , Effects of 5-methylpyrazole-3-carboxylic and (U-19,425) and nicotinic acid (NA) on free fatty acids (FFA), triglycerides (TG), and cholesterol in man. <i>Advan. Exp. Med. Biol.</i> (1969), 4, 213-26 | |
| | HH | KIENER, Enzymic oxidation of methyl groups in heteroarenes: a versatile method for the preparation of heteroaromatic carboxylic acids. <i>Angew. Chem., Int. Ed. Engl.</i> , 1992, 31(6), 774-5 | |
| | HI | AKTORIES <i>et al.</i> , Inhibition of adenylate cyclase and stimulation of a high affinity GTPase by the antilipolytic agents, nicotinic acid, aciplox and various related compounds. <i>Arzneimittel-Forschung</i> (1983), 33(11), 1525-7 | |
| Y.C.J. | HJ | PRYOR <i>et al.</i> , Purification of maize alcohol dehydrogenase and competitive inhibition by pyrazoles. <i>Biochemistry International</i> (1982), 4(4), 431-8 | |

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. Y.C.J.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 13 of 15

Complete if Known

| | |
|------------------------|---------------|
| Application Number | 10/560,332 |
| Filing Date | 09/08/2006 |
| First Named Inventor | Graeme Semple |
| Art Unit | 1614 |
| Examiner Name | Unknown |
| Attorney Docket Number | 59. US2.PCT |



NON PATENT LITERATURE DOCUMENTS

| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|---------------------|-----------------------|---|----------------|
| /Y.C./ | HK | BIZZI <i>et al.</i> , Effects of antilipolytic agents on glucose utilization by adipose tissue. <i>Biochemical Pharmacology</i> (1973), 22(6), 763-8 | |
| | HL | MYLES <i>et al.</i> , The development of tolerance to antilipolytic agents in rats. <i>Biochemical Pharmacology</i> (1985), 34(2), 269-74 | |
| | HM | STRATTON <i>et al.</i> , The development of tolerance to antilipolytic agents by isolated rat adipocytes. <i>Biochemical Pharmacology</i> (1985), 34(2), 275-9 | |
| | HN | COTTINEAU <i>et al.</i> , Synthesis and hypoglycemic evaluation of substituted pyrazole-4-carboxylic acids. <i>Bioorganic & Medicinal Chemistry Letters</i> (2002), 12(16), 2105-2108 | |
| | HO | HAMILTON <i>et al.</i> , The inhibition of mammalian D-amino acid oxidase by metabolites and drugs. Inferences concerning physiological function. <i>Bioorganic Chemistry</i> (1982), 11(3), 350-70 | |
| | HP | ISSEKUTZ, Effect of nicotinic acid, 5-methylpyrazole-3-carboxylic acid (U-19425), and dibutyl cyclic AMP on renal gluconeogenesis. <i>Canadian Journal of Physiology and Pharmacology</i> (1971), 49(2), 102-5 | |
| | HQ | REIMLINGER <i>et al.</i> , Syntheses with silver or sodium pyrazoles. II. Reactions of the silver salts of methylpyrazoles with halogens. <i>Chemische Berichte</i> (1970), 103(6), 1949-53 | |
| | HR | SEKIACHI <i>et al.</i> , Synthesis and chromophoric properties of symmetrical bis-heteroannulated diketopiperazines: diimidazo- and dipyrazolo-piperazinediones. <i>Dyes and Pigments</i> (1996), 32(1), 43-58 | |
| | HS | TIHANYI <i>et al.</i> , Pyrazolecarboxylic acid hydrazides as antiinflammatory agents. New selective lipoxigenase inhibitors. <i>European Journal of Medicinal Chemistry</i> (1984), 19(5), 433-9 | |
| | HT | BARALDI <i>et al.</i> , Synthesis, antibacterial activity and structure-activity relationships of N-substituted 4-diazopyrazole-5-carboxamides. 2. <i>Farmaco</i> (1991), 46(11), 1337-50 | |
| | HU | ALBERTI <i>et al.</i> , Alkylpyrazoles. <i>Farmaco, Edizione Scientifica</i> (1961), 16 527-39 | |
| | HV | ALEMAGNA <i>et al.</i> , Pyrazole synthesis from α -dicarbonyl compounds. <i>Gazzetta Chimica Italiana</i> (1963), 93(6), 748-56 | |
| | HW | INFANTES <i>et al.</i> , Packing modes in eight 3-ethoxycarbonylpyrazole derivatives. Influence of the substituents on the crystal structure and annular tautomerism. <i>Heterocycles</i> (1999), 50(1), 227-242 | |
| /Y.C./ | HX | BERINGER <i>et al.</i> , Attempts towards oral diabetes therapy by means of inhibition of lipolysis with 5-methylpyrazole-3-carboxylic acid. <i>Hormone and Metabolic Research</i> (1970), 2(2), 81-5 | |

| | |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450 DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /Y.C./

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 14 of 15

Complete if Known

| | |
|------------------------|---------------|
| Application Number | 10/560,332 |
| Filing Date | 09/08/2006 |
| First Named Inventor | Graeme Semple |
| Art Unit | 1614 |
| Examiner Name | Unknown |
| Attorney Docket Number | 59. US2.PCT |



NON PATENT LITERATURE DOCUMENTS

| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|---------------------|-----------------------|--|----------------|
| /Y.C./ | HY | MISHRA <i>et al.</i> , A heteroaromatic acid from marine sponge <i>Suberites vestigium</i> . <i>Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry</i> (1998), 37B(2), 199-200 | |
| | HZ | BANKS, Selectfluor reagent F-TEDA-BF4 in action: tamed fluorine at your service. <i>Journal of Fluorine Chemistry</i> (1998), 87(1), 1-17 | |
| | IA | MIETHCHEN <i>et al.</i> , Micelle-activated reactions. I. Micelle-activated iodination and partial dehalogenation of pyrazoles and 1,2,4-triazoles. <i>Journal fuer Praktische Chemie (Leipzig)</i> (1989), 331(5), 799-805 | |
| | IB | SAHA <i>et al.</i> , Mixed-ligand complexes of cobalt(II) and nickel(II) with 1-hydroxymethyl-5(3)-methylpyrazole-3(5)-carboxylic acid and heterocyclic amines. <i>Journal of the Indian Chemical Society</i> (1985), 62(2), 96-9 | |
| | IC | SAHA <i>et al.</i> , Synthesis, characterization and coordinating properties of a new benzimidazolopyrazole: cobalt(II), nickel(II) and copper(II) complexes of 5-methyl-3-(2'-benzimidazolyl)pyrazole. <i>Journal of the Indian Chemical Society</i> (1993), 70(11-12), 1035-42 | |
| | ID | PARAMESWARAN <i>et al.</i> , Secondary metabolites from the sponge <i>Tedania anhelans</i> : isolation and characterization of two novel pyrazole acids and other metabolites. <i>Journal of Natural Products</i> (1997), 60(8), 802-803 | |
| | IE | MANAEV <i>et al.</i> , Dimethylpyrazole-based syntheses. V. Nitration of 4-halopyrazole-3- and 5-carboxylic acids. <i>Zhurnal Obshchei Khimii</i> (1982), 52(11), 2592-8 | |
| | IF | AKTORIES <i>et al.</i> , Stimulation of a low Km GTPase by inhibitors of adipocyte adenylate cyclase. <i>Molecular Pharmacology</i> (1982), 21(2), 336-42 | |
| | IG | AKTORIES <i>et al.</i> , In vivo and in vitro desensitization of nicotinic acid-induced adipocyte adenylate cyclase inhibition. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> (1982), 318(3), 241-5 | |
| | IH | FRANCESCHI <i>et al.</i> , Synthesis and aggregation of two-headed surfactants bearing amino acid moieties. <i>New Journal of Chemistry</i> (1999), 23(4), 447-452 | |
| | II | OGAWA <i>et al.</i> , Identification of metabolites of the acaricide, teflubenzpyrad, formed in vivo and in vitro systems of rats. <i>Nippon Noyaku Gakkaishi</i> (1994), 19(3), 169-79 | |
| | IJ | TAKASAKI <i>et al.</i> , Hypoglycemic activity of certain heterocyclic acid derivatives. <i>Nippon Yakurigaku Zasshi</i> (1973), 69(6), 977-94 | |
| ✓ | IK | CABILDO <i>et al.</i> , Carbon-13 NMR chemical shifts of N-unsubstituted and N-methylpyrazole derivatives. <i>Organic Magnetic Resonance</i> (1984), 22(9), 603-7 | |
| /Y.C./ | IL | SAHA <i>et al.</i> , Design, synthesis and spectroscopic characterization of palladium(II) and platinum(II) complexes of pyrazole-derived ligands with potential anti-tumor properties in its historical perspective. <i>Polyhedron</i> (1994), 13(13), 2025-33 | |

| | |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /Y.C./

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 15 of 15

Complete if Known

| | |
|------------------------|---------------|
| Application Number | 10/560,332 |
| Filing Date | 09/08/2006 |
| First Named Inventor | Graeme Sample |
| Art Unit | 1614 |
| Examiner Name | Unknown |
| Attorney Docket Number | 59. US2.PCT |

**NON PATENT LITERATURE DOCUMENTS**

| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|---------------------|-----------------------|---|----------------|
| /Y.C./ | IM | KOJIMA <i>et al.</i> , Renal excretion of sodium 4-iodo-5-methylpyrazole-3-carboxylate-1311. <i>Radioisotopes</i> (1979), 28(5), 300-5 | |
| | IN | BARALDI <i>et al.</i> , An efficient procedure for the synthesis of 5H-6-substituted pyrazolo[1,5-d]-1,2,4-triazine-4,7-diones. <i>Synthesis</i> (1999), (3), 453-458 | |
| | IO | FLORES <i>et al.</i> , Synthesis of hydroxypyrazoles and 1-methyl-3-isoxazolones via haloform reactions. <i>Tetrahedron Letters</i> (2002), 43(28), 5005-5008 | |
| | IP | PIKE <i>et al.</i> , Identification of a nicotinic acid receptor: Is this the molecular target for the oldest lipid-lowering drug? <i>Current Opinion in Investigational Drugs</i> (Thomson Scientific) (2004), 5(3), 271-275 | |
| | IQ | OFFERMANN, The nicotinic acid receptor GPR109A (HM74A or PUMA-G) as a new therapeutic target. <i>Trends in Pharmacological Sciences</i> (2006), 27(7), 384-390 | |
| | IR | BARIANA <i>et al.</i> , Nicotinic acid esters as coronary vasodilators. <i>Journal of Medicinal Chemistry</i> (1971), 14(4), 372-3 | |
| /Y.C./ | IS | HOLLAND <i>et al.</i> , Heterocyclic tetrazoles, a new class of lipolysis inhibitors. <i>Journal of Medicinal Chemistry</i> (1967), 10(2), 149-54 | |

| | | | |
|--------------------|------------|-----------------|------------|
| Examiner Signature | /Yong Chu/ | Date Considered | 02/20/2008 |
|--------------------|------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /Y.C./